Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma

Meritxell Deulofeu1,2,3, Lenka Kolářová4, Victoria Salvadó5, Eladia María Peña-Méndez6, Martina Almáši7, Martin Štork8, Luděk Pour8, Pere Boadas-Vaello2,3, Sabina Ševčíková9, Josef Havel4,10 & Petr Vaňhara1,10

Multiple myeloma (MM) is a highly heterogeneous disease of malignant plasma cells. Diagnosis and monitoring of MM patients is based on bone marrow biopsies and detection of abnormal immunoglobulin in serum and/or urine. However, biopsies have a single-site bias; thus, new diagnostic tests and early detection strategies are needed. Matrix-Assisted Laser Desorption/Ionization Time-of Flight Mass Spectrometry (MALDI-TOF MS) is a powerful method that found its applications in clinical diagnostics. Artificial intelligence approaches, such as Artificial Neural Networks (ANNs), can handle non-linear data and provide prediction and classification of variables in multidimensional datasets. In this study, we used MALDI-TOF MS to acquire low mass profiles of peripheral blood plasma obtained from MM patients and healthy donors. Informative patterns in mass spectra served as inputs for ANN that specifically predicted MM samples with high sensitivity (100%), specificity (95%) and accuracy (98%). Thus, mass spectrometry coupled with ANN can provide a minimally invasive approach for MM diagnostics.

Monoclonal gammopathies are a group of diseases characterized by increased amounts of abnormal immunoglobulin produced by a clone of plasma or lymphoid cells. This abnormal immunoglobulin is present in serum and/or urine in the form of entire molecule or its fragments. Monoclonal gammopathies range from benign (MGUS – monoclonal gammopathy of undetermined significance) to malignant (multiple myeloma, plasma cell leukemia, etc)1.

Multiple myeloma (MM) is a highly heterogeneous disease of malignant plasma cells (PC) that abrogate physiological hematopoiesis in the bone marrow; these cells are heavily dependent on the bone marrow microenvironment for survival2. Diagnosis of MM is currently based on: presence of monoclonal PC in the bone marrow (>10%), presence of one or more CRAB symptoms (hyperCalcemia, Renal failure, Anemia, Bone lesions) or presence of at least one biomarker of malignancy (more than 60% of clonal PC in the bone marrow, more than one bone lesion on MRI, ratio of involved/uninvolved serum light chains >100)3. MM comprises about 13% of

1Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
2Research Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, University of Girona, Girona, Spain. 3Experimental Neurophysiology and Clinical Anatomy (NE&AC), 2017 SGR 01279, Department of Medical Sciences, University of Girona,Girona, Spain. 4Department of Chemistry, Faculty of Science, Masaryk University, Brno, Czech Republic. 5Department of Chemistry, Faculty of Science, University of Girona, Girona, Spain. 6Department of Chemistry, Analytical Chemistry Division, Faculty of Science, University of La Laguna, La Laguna, Spain. 7Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. 8Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. 9Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 10International Clinical Research Center, St. Anne’s University Hospital, Brno, Czech Republic. Correspondence and requests for materials should be addressed to P.V. (email: pvanhara@med.muni.cz)
hematological malignancies and around 1% of all cancers. Its incidence in Europe is 6/100 000 per year. In the Czech Republic, the incidence is slightly lower, reported at 4.8/100 000 per year. Median age at diagnosis is 65.

Unlike other hematological malignancies that oftentimes contain a single genetic aberration that may be targeted for diagnosis, follow-up or treatment, MM is characterized by as many as seven aberrations at the time of diagnosis; this number usually increases in time. Moreover, the nature of MM makes treatment even more difficult as there are focal lesions of PC clones in the bone marrow. These clones compete for access to the bone marrow niche and evolve into a complex spatiotemporal ecosystem. At times, they may be the reason for treatment failure. Moreover, other clones may be found in various parts of the body directly influencing survival of patients. In recent years, the so-called liquid biopsies, analyzing circulating cells and molecules outside of the bone marrow, are gaining in importance. In MM, bone marrow biopsy is still the golden standard for diagnosis. However, this single-site analysis may not give comprehensive information about the disease, as the clones may be located in other parts of the body. Therefore, novel diagnostic approaches for detection of MM are needed.

Techniques adopted from analytical chemistry, such as mass spectrometry (MS), may provide robust and precise tools for revealing potential disease biomarkers. In cancer biology, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS is a powerful and highly sensitive tool for the detection of large numbers of peptides and proteins in serum. MS-based profiling has been applied to develop new potential biomarkers in many types of cancer, such as renal, lung, liver, breast, colon, prostate and ovarian cancer. Particularly in MM, only few studies have been conducted to not only potential diagnostic markers and classification markers, but also markers associated with treatment response. All of them, however, require complex sample handling which increases the cost and the time to diagnosis. Thus, a different, easier and faster method is necessary.

Discrimination of disease-specific molecular patterns in peripheral blood of MM patients can provide a promising approach for early diagnostics and follow-up. Despite recent discoveries of potential low molecular mass biomarkers associated with MM, the direct applicability of metabolomics markers is still limited.

Artificial Neural Networks (ANNs) represent a mathematical tool capable of handling non-linear data and providing generalization and prediction of complex variables in multidimensional datasets. Therefore, ANNs are highly suitable for pattern recognition, classification and modelling. ANNs have been widely applied in different fields of clinical diagnostics (for review see ref.34).

We have demonstrated previously, that ANN can recognize informative patterns in mass spectra acquired from diseased tissues or stem cells cultures. In this study, we were curious whether information hidden in complex spectral patterns can provide a suitable input for ANNs to classify low mass spectral profiles of MM patients and age/sex-matched healthy donors. Such approach may represent a promising tool for diagnostics or follow up of MM patients, and also for revealing non-standard patient’s cases and/or the heterogeneity of the disease. Here we have for the first time demonstrated that MALDI-TOF MS coupled with ANNs specifically recognizes healthy and diseased samples and correctly classifies MM patients.

**Results and Discussion**

We recorded mass spectra of 20 MM and 20 healthy donor (HD) samples and constructed a dataset assigned as “training”. The mass spectra were highly similar, without any apparent, constantly reproducible single peak(s) correlating to class identifiers. Rather, variable regions containing multiple peaks with lower intensity were identified. Previously, we showed that while a single-peak is either non-informative or suffers from non-linear relationships in quantitative assessments, combination of several peaks may represent a more suitable input. In total, 28 peaks with varying intensities were used for calculations (Fig. 1A). First, we estimated the level of similarity in mass spectra constituting the training dataset using a heat map of Pearson’s correlations. Interestingly, the intrinsic variability of the MM cohort was higher than in HD cohort, suggesting a wider range of metabolic divergences in MM samples. Importantly, the heterogeneity between MM and HD samples was higher than within individual MM and HD datasets (Fig. 1B). This prompted us to perform principal component analysis (PCA) to discriminate the training and validation datasets (Fig. 2A,B) using the full spectral matrix as input. Eigenvalue analysis showed that most of the overall variability within the system can be explained by presence of only two factors, corresponding to MM and HD cohorts (Fig. 2C,D). Thus, we documented that spectral profiles contain sufficient information for discrimination of healthy and MM samples in a single coherent dataset.

To independently validate the observations, we constructed a back-propagation multilayer perceptron ANN (Fig. 3A). The optimal network architecture was validated by plotting the Root Mean Square Error (RMS) against the number of nodes (data not shown). The robustness was demonstrated by performing >50,000 training cycles (epochs) without significant overfitting the ANN model. First, the leave-one-out cross-validation method was used to test the neural network to predict single cases within the training dataset with 100% of correct predictions. However, when we randomly decreased number of peaks in the spectral matrix entering the analysis, the error rate was significantly increased (Fig. 3B). This suggests that the dataset lacks a dominant “marker peak” associated with sample class, and the discriminating capacity of mass spectra is dependent on the cumulative contributions of alterations in more molecular species. Thus, the non-reduced mass spectrum can provide a global marker for prediction of MM.

Then, we established the validation dataset consisting of additional 24 MM and 20 HD samples measured independently on the same instrument. While the PCA correctly classified the MM and HD cohorts within the validation dataset, it failed in case of merged training and validation datasets. Interestingly, the inter-experimental variability introduced a significant bias to the analysis, as the PCA clustered the merged dataset according to the experiment (event of measurement) suffering from the sensitivity to systematic errors (data not shown). When the trained ANN was used to predict classification for the independent validation dataset, 42 cases out of 44 were correctly classified as HD or MM (Fig. 3C, Table 1).

In concordance to the training set, the validation ANN analysis was dependent on the number of input signals, confirming the initial observations (data not shown). Similar results were obtained when we recapitulated
the study on a different MALDI-TOF MS instrument (AXIMA Resonance). In summary, we demonstrated for the first time that peripheral blood plasma of MM patients contains specific spectral fingerprints corresponding to alterations of low mass molecular species, which might be used for disease prediction or revealing druggable metabolic pathways.

Several studies suggested that metabolomics is a new and powerful tool usable for identification of early biomarkers related with inborn disorders of metabolism, cardiovascular diseases and cancer. This approach allows for analysis of small molecules that characterize metabolic pathways. Generally, two approaches have been used so far: nuclear magnetic resonance spectroscopy (H-NMR) and mass spectrometry (MS). Using H-NMR, Puchades Carrasco et al.\textsuperscript{18} showed differences in metabolomics profiles of MM patients (at diagnosis and CR) versus healthy donors. This study showed that while MM patients at diagnosis had a different metabolomics profile in comparison to healthy donors, once they reached CR, they had closer metabolic profiles to healthy donors. A newer study by Medriano et al.\textsuperscript{28} used liquid chromatography coupled to mass spectrometry to assess metabolomics in MM and non-Hodgkin lymphoma patients in comparison to healthy donors. They found a clear metabolic difference in samples of cancer patients in comparison to healthy donors. The observed affected pathways, such as oxidative phosphorylation and choline metabolism, were those linked to tumor growth and progression. Another study using compared metabolomics profiles of samples of MGUS, MM patients (both at diagnosis and at relapse) and found that all three groups of patients had significantly different profiles from healthy donors. Pathway analyses revealed a distinct metabolic profile with significant alterations in amino acid, lipid, and energy metabolism in healthy donors compared to MGUS/MM patients\textsuperscript{29}.

**Figure 1.** (A) Box and whisker plot demonstrating varying intensity of 28 peaks of distinct \textit{m/z} in the training dataset (line: mean; box: 95% confidence intervals; whiskers: standard deviations). (B) Heat map of Pearson’s correlations based on spectral fingerprints in the training dataset.
MALDI-TOF MS–driven approach in MM was first suggested by Wang et al. in 2008. In their work, the authors identified 56 unique m/z signals ranging from m/z 2015 to 24070, with varying intensities between MM and healthy donors and demonstrated that three of them are of a potential prognostic significance. In our work, we revealed potentially informative spectral regions in lower m/z values (<1000 Da) of peripheral blood plasma and documented that they can serve as suitable inputs for reliable ANN-based diagnostics. In conclusion, we envisage that disease related spectral fingerprints coupled with artificial intelligence can provide a complementary, minimally-invasive tool for diagnostics and follow-up of MM patients.

Material and Methods

Chemicals. Sinapinic acid, trifluoroacetic acid, and Micro-90® concentrated cleaning solution were purchased from Sigma-Aldrich (Prague, Czech Republic). Acetonitrile (purity for isotachophoresis) was purchased from Merck (Darmstadt, Germany). Red phosphorus was purchased from Riedel de Haén (Hannover, Germany). Water was double distilled using a quartz apparatus from Heraeus Quarzschmelze (Hanau, Germany). All other reagents were of analytical grade purity. IVD bacterial test standard (BTS) was purchased from Bruker Daltonik GmbH (Bremen, Germany).

Sample collection and preparation. In total, 84 samples of plasma of peripheral blood acquired from 44 MM patients and 40 age- and sex-matched HD, were included in the analysis (Table 2). The total cohort was randomly divided into the training and validation dataset consisting of 20 MM and 20 HD samples, and 24 MM and 20 HD samples, respectively. The training and validation sets were processed and measured independently. All MM patients were diagnosed at the University Hospital Brno, Czech Republic and included into the study only after they signed the informed consent form approved by the Ethics committee of the University Hospital Brno, and Ethics committee of the Faculty of Medicine, Masaryk University, in accordance with the current version of the Helsinki Declaration. All patients' samples were collected at the time of diagnosis prior to treatment. Peripheral blood was stabilized in EDTA, centrifuged at 2000 g for 15 min at 20 °C. Aliquoted plasma samples were stored at −80 °C and thawed only once prior to analysis.

Sample preparation for MS. Samples of plasma were thawed and processed on ice. All samples were diluted ten times with double distilled water and mixed in 1:1 ratio with solution of sinapinic acid (SA) containing 20 mg/ml SA in 50% acetonitrile supplemented with 0.3% trifluoroacetic acid. 1 μl of the mixture was spotted on purified stainless steel target plate in three replicates. To avoid carry-over contamination, the target plate was regularly cleaned with specific cleaning procedure in an ultrasonic bath with ultrapure solvents sequentially in this order: methanol, acetone, 5% Micro-90, water, methanol, water and then dried before spotting the samples.
Acquisition of mass spectra. Mass spectra were acquired using Axima CFR with Time-Of-Flight (TOF) analyzer and validated using AXIMA Resonance TOF mass spectrometer from Kratos Analytical Ltd. (Manchester, UK). Both devices are equipped with a nitrogen laser (337 nm), delayed extraction, and micro-channel plate detector. The laser energy was expressed in arbitrary units (scale 0 to 180 a.u.). The laser power and fluence at the maximum laser energy were 6 mW and $\approx 10 \text{ mJ/mm}^2/\text{pulse}$, respectively. The accelerating voltage

![Figure 3.](image)

(A) Architecture of the artificial neural network used for the prediction of sample class (MM, HD). (B) Plot documenting prediction capability of the ANN based on 7, 14 or 28 input peaks. (C) Plots documenting ANN classification outputs in the training and validation dataset.

| Dataset     | Training          | Verification        |
|-------------|-------------------|---------------------|
| Cases       | 40 (20 MM, 20 HD) | 44 (24 MM, 20 HD)   |
| True positive (MM) | 20 (100%)   | 23 (95.83%)         |
| True negative (HD) | 20 (100%)  | 19 (95.00%)         |
| False positive | 0             | 1 (5.00%)           |
| False negative | 0             | 0                   |
| Unidentified  | 0              | 1 (4.17%)*          |
| Sensitivity [%] | 100%        | 95.83%              |
| Specificity [%]  | 100%         | 95.00%              |
| Accuracy [%]    | 100%          | 95.45%              |

Table 1. Results of ANN classification. *Unidentified case (MM) arbitrarily classified as false negative.
was set to 20 kV and laser repetition to 5 Hz. All measurements were carried out at $10^{-4}$ Pa pressure in the TOF tube. Mass spectra obtained in ranges $m/z$ 0–10 000 from 2500 laser shots using regular raster are displayed as the ion signal to the $m/z$ value. The spectra were normalized meaning that the intensity of the maximum peak was equal to 100%. Calibration was performed using phosphorus clusters as described elsewhere or a bacterial test standard with an accuracy of 0.01 Da. The Launchpad software (Kompact version 2.3.4, 2003) from Kratos Analytical Ltd. was used to evaluate and export the mass spectra to ASCII. The smoothing of mass spectra by Savitzky-Golay method, baseline subtraction by LOESS method, and spectral alignment, were performed in the R-program. Only reproducible peaks with intensities over the signal:noise $>3$ were included to the analysis. In total, 28 informative peaks with minimal inter-experimental variability, and sufficient variability between cohorts, were selected from all technically available peaks.

Table 2. Experimental cohorts entering the analysis.

| Group                  | n  | Gender | Age median (min-max) [years] |
|------------------------|----|--------|-----------------------------|
| Training cohort        |    |        |                             |
| Healthy donor          | 20 | M=10   | 67 (51–66)                  |
| Multiple myeloma       | 20 | M=10   | 67 (57–83)                  |
| Validation cohort      |    |        |                             |
| Healthy donor          | 20 | M=10   | 56 (54–64)                  |
| Multiple myeloma       | 24 | M=12   | 71 (47–95)                  |

Statistical analysis. Pearson’s correlations, principal component analyses (PCA) and determination of eigenvalues were done in Statistica 6.0 (StatSoft, Inc., Tulsa, USA). Artificial neural networks were constructed and run in TRAJAN Neural Network Simulator, Release 3 (Trajan Software Ltd., Durham, UK). The ANN contained 28 input nodes corresponding to the number of peak intensities, four nodes in the hidden layer and the output layer. The network was trained using conjugate gradient descent training algorithm, with maximum number of iterations 50,000. Classification confidence level was set to 0.05. Values of continuous variables over 0.95 or below 0.05 were considered as the decision outputs to a discrete class. Values between 0.05 and 0.95 were classified as unknown. Cases that were not identified by ANN (decision output “unknown”) were arbitrarily classified as wrong predictions in the respective cohort.

Ethics statement. All experiments were performed in accordance with relevant guidelines and regulations. Informed consent for study participation was obtained for each patient included. The study was approved by the Ethics committee of the University Hospital Brno (approval date February 2, 2017), and by the Ethics committee of the Faculty of Medicine, Masaryk University (approval date June 22, 2016, no.: 21/2016).

Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author upon request.

References
1. Attelbermann, M. & Levinson, S. S. Understanding and identifying monoclonal gammopathies. Clin. Chem. 46, 1230–1238 (2000).
2. Kyle, R. A. & Rajkumar, S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23, 3–9 (2009).
3. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–548 (2014).
4. Dimopoulos, M. A. & Terpos, E. Multiple myeloma. Ann. Oncol. 21, vii143–150 (2010).
5. Maluskova, D. et al. Epidemiology of Multiple Myeloma in the Czech Republic. Klin.Onkol. 30, 35–42 (2017).
6. Hajek, R., Bryce, R., Ro, S., Klencke, B. & Ludwig, H. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer 12, 415–422 (2012).
7. Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587–597 (2018).
8. Kubaczkova, V. et al. Liquid Biopsies - the Clinics and the Molecules. Klin. Onkol. 30, 13–2 (2017).
9. Tolson, J. et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab. Invest. 84, 845–856 (2004).
10. Jin, H. et al. Discrimination Analysis of Mass Spectrometry Proteomics for Lung Adenocarcinoma Detection. Lab Medicine 42, 344–349 (2011).
11. Steel, L. F. et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3, 601–609 (2003).
12. Pietrowska, M. et al. Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J. Transl. Med. 7, 60–73 (2009).
13. Pietrowska, M. et al. Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. J. Transl. Med. 8, 66–77 (2010).
14. Roessler, M. et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer. Res. 11, 6550–6557 (2005).
15. Grizzle, W. E. et al. The Early Detection Research Network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology. Urol. Oncol. 22, 337–343 (2004).
16. Kozak, K. R. et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. USA 100, 12343–12348 (2003).
17. He, A. L. et al. Detection of serum tumor markers in multiple myeloma using the CLINPROT system. *Int. J. Hematol.* **95**, 668–674 (2012).
18. Puchades-Carrasco, L. et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. *Clin. Cancer Res.* **19**, 4770–4779 (2013).
19. Wang, Q. T. et al. Construction of A Multiple Myeloma Diagnostic Model by Magnetic Bead-Based MALDI-TOF Mass Spectrometry of Serum and Pattern Recognition Software. *Anat. Rec.* **292**, 604–610 (2009).
20. Zhang, H. T., Tian, E. B., Chen, Y. L., Deng, H. T. & Wang, Q. T. Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma. *Chin. Med. J.* **128**, 1108–1113 (2015).
21. Bhattacharyya, S., Epstein, J. & Suva, L. J. Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. *Dis.Markers* **22**, 245–255 (2006).
22. Dowling, P. et al. Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. *BMC Genomics* **15**, 904–916 (2014).
23. Basheer, I. A. & Hajmeer, M. Artificial neural networks: fundamentals, computing, design, and application. *J. Microbiol. Methods* **43**, 3–31 (2000).
24. Amato, F. et al. Artificial neural networks in medical diagnosis. *J. Appl. Biomed.* **11**, 47–58 (2013).
25. Valletta, E. et al. Multivariate Calibration Approach for Quantitative Determination of Cell-Line Cross Contamination by Intact Cell Mass Spectrometry and Artificial Neural Networks. *PLoS ONE* **11**, e0147414 (2016).
26. Houska, J. et al. Tissue profiling by nanogold-mediated mass spectrometry and artificial neural networks in the mouse model of human primary hyperoxaluria I. *J. Appl. Biomed.* **12**, 119–125 (2014).
27. Vanhara, P. et al. Intact Cell Mass Spectrometry as a Quality Control Tool for Revealing Minute Phenotypic Changes of Cultured Human Embryonic Stem Cells. *Stem Cells Transl. Med.* **7**, 109–114 (2018).
28. Medriano, C. A. D., Na, J., Lim, K. M., Chung, J. H. & Park, Y. H. Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients. *Cell J.* **19**, 44–54 (2017).
29. Steiner, N. et al. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. *PLoS ONE* **13**, e0202045 (2018).
30. Kolarova, L. et al. Clusters of Monoisotopic Elements for Calibration in (TOF) Mass Spectrometry. *J. Am. Soc. Mass. Spectrom.* **28**, 419–427 (2017).
31. Gibb, S. & Strimmer, K. MALDIquant: a versatile R package for the analysis of mass spectrometry data. *Bioinformatics* **28**, 2270–2271 (2012).
32. Baptista, D. & Morgado-Dias, F. A survey of artificial neural network training tools. *Neural Comput. Appl.* **23**, 609–615 (2013).

**Acknowledgements**

This work was supported by Ministry of Health of the Czech Republic, grants nr. NV18-08-00299 and AZV17-29343A, the National Program of Sustainability II (Project No. LQ1605, MEYS CR), and by Masaryk University (MUNI/A/1298/2017).

**Author Contributions**

M.D.F. and L.K. acquired the experimental data, P.V., J.H. and S.S. contributed to conception and design and wrote the main manuscript text, P.V. and M.D.F. prepared the figures, S.S., M.A., M.S. and L.P. contributed to sample preparation, J.H., E.M.P., P.B.V. and V.S. contributed to data analysis and interpretation, and critically revised the manuscript. All authors reviewed the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

This work was supported by Ministry of Health of the Czech Republic, grants nr. NV18-08-00299 and AZV17-29343A, the National Program of Sustainability II (Project No. LQ1605, MEYS CR), and by Masaryk University (MUNI/A/1298/2017).

**Author Contributions**

M.D.F. and L.K. acquired the experimental data, P.V., J.H. and S.S. contributed to conception and design and wrote the main manuscript text, P.V. and M.D.F. prepared the figures, S.S., M.A., M.S. and L.P. contributed to sample preparation, J.H., E.M.P., P.B.V. and V.S. contributed to data analysis and interpretation, and critically revised the manuscript. All authors reviewed the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).